LOS ANGELES (Reuters) – Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10... More »
FILE PHOTO: FILE PHOTO: Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) – Roche announced a double dose of trial wins on Monday, saying its immunotherapy Tecen... More »
Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said. More »
A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumor, potentially helping to predict which patients may respond best to some immunotherapies. More »
